Altman, D. G. and Royston, P. (2006). The cost of dichotomising continuous variables. BMJ, 332, 1080.
Beck, A. T., Epstein, N., Brown, G. and Steer, R. A. (1988). An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology, 56, 893–897.
Beck, A. T., Steer, R. A. and Brown, G. K. (1996). BDI-II, Beck Depression Inventory: Manual. San Antonio, TX; Boston, MA: Psychological Corp.; Harcourt Brace.
Bjelland, I., Lie, S. A., Dahl, A. A., Mykletun, A., Stordal, E. and Kraemer, H. C. (2009). A dimensional versus a categorical approach to diagnosis: anxiety and depression in the HUNT 2 study. International Journal of Methods in Psychiatric Research, 18, 128–137.
Braak, H. and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82, 239–259.
Brendel, M., Pogarell, O., Xiong, G., Delker, A., Bartenstein, P. and Rominger, A. (2015). Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. European Journal of Nuclear Medicine and Molecular Imaging, 42, 716–724.
Butters, M. A.
et al. (2008). Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Disease and Associated Disorders, 22, 261–268.
et al. (2012). Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegenerative Diseases, 10, 141–144.
Choi, S. H.
et al. (2014). A three-dimensional human neural cell culture model of Alzheimer's disease. Nature, 515, 274–278.
Chung, J. K.
et al. (2016). Cortical amyloid beta deposition and current depressive symptoms in Alzheimer disease and mild cognitive impairment. Journal of Geriatric Psychiatry and Neurology, 29, 149–159.
Cole, G. B.
et al. (2010). Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proceedings of the National Academy of Sciences of the United States of America, 107, 6222–6227.
Donovan, N. J.
et al. (2015). Depressive symptoms and biomarkers of Alzheimer's disease in cognitively normal older adults. Journal of Alzheimer's Disease, 46, 63–73.
et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734–746.
Geda, Y. E.
et al. (2006). Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Archives of Neurology, 63, 435–440.
Geda, Y. E.
et al. (2008). Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Archives of General Psychiatry, 65, 1193–1198.
Geda, Y. E.
et al. (2014). Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. American Journal of Psychiatry, 171, 572–581.
Hardy, J. and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353–356.
Harrington, K. D.
et al. (2017). Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 32, 455–463.
Harrington, K. D., Lim, Y. Y., Gould, E. and Maruff, P. (2015). Amyloid-beta and depression in healthy older adults: a systematic review. Australian and New Zealand Journal of Psychiatry, 49, 36–46.
Holmes, S. E.
et al. (2016). beta-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. The American Journal of Geriatric Psychiatry, 24, 1191–1195.
et al. (2016). Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimer's and Dementia, 12, 195–202.
Ivnik, R. J.
et al. (1992b). Mayo's older americans normative studies: updated AVLT norms for ages 56 to 97. Clinical Neuropsychologist, 6, 83–104.
Ivnik, R. J.
et al. (1992c). Mayo's older Americans normative studies: WAIS-R norms for ages 56 to 97. Clinical Neuropsychologist, 6, 1–30.
Ivnik, R. J.
et al. (1992d). Mayo's older americans normative studies: WMS-R norms for ages 56 to 94. Clinical Neuropsychologist, 6, 49–82.
et al. (1992a). Mayo's older americans normative studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clinical Neuropsychologist, 6, 1–104.
Jack, C. R.
et al. (2010). Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 133, 3336–3348.
Jack, C. R., Barrio, J. R. and Kepe, V. (2013). Cerebral amyloid PET imaging in Alzheimer's disease. Acta Neuropathologica, 126, 643–657.
Jagust, W. J.
et al. (2010). The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimer's & Dementia, 6, 221–229.
Knopman, D. S.
et al. (2012). Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology, 78, 1576–1582.
et al. (2016). FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: the mayo clinic study of aging. Journal of Alzheimer's disease, 53, 1609–1616.
et al. (2014). Subsyndromal depression among older adults in the USA: prevalence, comorbidity, and risk for new-onset psychiatric disorders in late life. International Journal of Geriatric Psychiatry, 30, 677–685.
Malec, J. F.
et al. (1992). Mayo's older americans normative studies: utility of corrections for age and education for the WAIS-R. Clinical Neuropsychologist, 6, 31–47.
Morris, J. C.
et al. (2009). Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology, 66, 1469–1475.
Murray, M. E.
et al. (2015). Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain, 138, 1370–1381.
Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256, 183–194.
Petersen, R. C.
et al. (2016). Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurology, 73, 85–92.
Pietrzak, R. H.
et al. (2014). Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. British Journal of Psychiatry, 204, 400–401.
Pietrzak, R. H.
et al. (2015). Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry, 72, 284–291.
et al. (2015). Neuropsychiatric symptoms, APOE epsilon4, and the risk of incident dementia: a population-based study. Neurology, 84, 935–943.
et al. (2017). Cortical thickness and anxiety symptoms among cognitively normal elderly persons: the mayo clinic study of aging. The Journal of Neuropsychiatry and Clinical Neurosciences, 29, 60–66.
Roberts, R. O.
et al. (2008). The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology, 30, 58–69.
Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M. and Trojanowski, J. Q. (2007). Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews. Drug Discovery, 6, 295–303.
Sperling, R. A.
et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7, 280–292.
et al. (2004). Mild cognitive impairment–beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. Journal of Internal Medicine, 256, 240–246.